Form 4: ALNY CSO Gains Shares, Sells for Tax Cover

Alnylam Pharmaceuticals' CSO and EVP, Kevin Fitzgerald, acquired 2,851 shares through PSU vesting and sold 1,396 shares to cover tax obligations.

Summary

• Kevin Fitzgerald, CSO & EVP, Head of Research, acquired 2,851 shares of Alnylam Pharmaceuticals (ALNY) common stock on August 15, 2025, through the vesting of performance-based stock units (PSUs) granted on March 1, 2024.
• The vesting was based on the achievement of a clinical milestone, as determined by the Issuer's People, Culture and Compensation Committee.
• On August 18, 2025, Fitzgerald sold a total of 1,396 shares of common stock in multiple transactions at weighted average prices ranging from $447.98 to $455.82.
• These sales were automatic 'sell-to-cover' transactions to meet minimum statutory tax withholding obligations upon the vesting and settlement of a tranche of restricted stock units granted on March 1, 2024.
• An additional 537 shares of ALNY common stock were acquired indirectly by Fitzgerald through a managed account via the issuer's 401(k) matching contribution program.
• Following these transactions, Fitzgerald directly beneficially owns 22,719 shares and indirectly owns 537 shares.

Sentiment

Score: 7

Explanation: The filing indicates the achievement of a clinical milestone, leading to PSU vesting, which is a positive operational sign. The sales are routine tax-related transactions, not indicative of negative sentiment. The overall sentiment is moderately positive due to the milestone achievement.

Positives

• Vesting of 2,851 performance-based stock units indicates the achievement of a clinical milestone, suggesting progress in the company's research and development pipeline.
• The acquisition of 537 shares through the 401(k) matching program reflects ongoing employee participation and benefit from company performance.

Negatives

• The sale of 1,396 shares, while for tax purposes, represents a reduction in direct beneficial ownership by a key executive.

Future Outlook

The filing indicates the achievement of a clinical milestone, which is a positive indicator for future product development, though no specific forward-looking guidance on financial performance or timelines is provided.

Management Comments

• The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025.
• Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

Industry Context

This Form 4 filing reflects routine insider compensation and tax-related transactions common in the biotechnology and pharmaceutical industries, where executive compensation often includes equity awards tied to performance milestones. The achievement of a clinical milestone is a standard measure of progress in drug development, which is critical for companies like Alnylam.

Comparison to Industry Standards

• The use of performance-based stock units (PSUs) and restricted stock units (RSUs) tied to clinical milestones is a common compensation practice in the biotechnology sector, aligning executive incentives with R&D success.
• 'Sell-to-cover' transactions for tax obligations upon equity vesting are standard industry practice and do not typically indicate a lack of confidence in the company. For example, executives at companies like Moderna (MRNA) or BioNTech (BNTX) frequently engage in similar transactions when equity awards vest.
• The achievement of a clinical milestone, while specific to Alnylam's pipeline, is a key value driver comparable to similar progress reported by peers such as Ionis Pharmaceuticals (IONS) or Sarepta Therapeutics (SRPT) in their respective therapeutic areas.

Stakeholder Impact

• Shareholders: The achievement of a clinical milestone could positively impact shareholder value by de-risking the pipeline and demonstrating R&D progress. The insider's increased beneficial ownership (net of sales) aligns executive interests with shareholders.
• Employees: The 401(k) matching contribution program benefits employees.

Next Steps

• Continued progress on the remaining performance measures for the outstanding PSUs.
• Further clinical development and potential regulatory milestones related to the achieved clinical milestone.

Key Dates

Recommendation

This Form 4 filing primarily details routine insider transactions related to executive compensation and tax obligations. While the vesting of performance-based stock units due to a clinical milestone is a positive operational indicator, the sales are mandatory 'sell-to-cover' and do not reflect a discretionary decision to reduce exposure. The filing does not provide new material information that would warrant a change in investment thesis or a strong buy/sell recommendation. Investors should continue to hold based on broader company fundamentals and pipeline progress.

Keywords

Alnylam Pharmaceuticals, ALNY, Insider Trading, Form 4, Stock Vesting, Performance Stock Units, Restricted Stock Units, Executive Compensation, Biotechnology, Pharmaceuticals